Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Focus on GH deficiency and thyroid function.

Giavoli C, Profka E, Rodari G, Lania A, Beck-Peccoz P.

Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):71-78. doi: 10.1016/j.beem.2017.02.003. Epub 2017 Feb 24. Review.

PMID:
28477734
2.

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.

Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BMK.

Eur J Endocrinol. 2017 Mar;176(3):283-294. doi: 10.1530/EJE-16-0748. Epub 2016 Dec 8.

3.

Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects.

Cohen-Barak O, Barkay H, Rasamoelisolo M, Butler K, Yamada K, Bassan M, Yoon E, Spiegelstein O.

Clin Pharmacol Drug Dev. 2017 Jul;6(4):331-342. doi: 10.1002/cpdd.294. Epub 2016 Sep 21.

4.

Growth, development, puberty and adult height of patients with congenital multiple pituitary hormone deficiencies.

Haim-Pinhas H, Kauli R, Lilos P, Laron Z.

Growth Horm IGF Res. 2016 Apr;27:46-52. doi: 10.1016/j.ghir.2016.01.004. Epub 2016 Feb 19.

PMID:
26947989
5.

Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.

Lewis AL, Jordan F, Patel T, Jeffery K, King G, Savage M, Shalet S, Illum L.

J Clin Endocrinol Metab. 2015 Nov;100(11):4364-71. doi: 10.1210/jc.2014-4146. Epub 2015 Oct 1.

6.

Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.

Laron Z, Kauli R.

Growth Horm IGF Res. 2016 Jun;28:53-6. doi: 10.1016/j.ghir.2015.08.004. Epub 2015 Aug 18.

PMID:
26307357
7.

A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.

Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1819-29. doi: 10.1210/jc.2014-1702. Epub 2014 Jul 11.

PMID:
25013997
8.

Head circumference in untreated and IGF-I treated patients with Laron syndrome: comparison with untreated and hGH-treated children with isolated growth hormone deficiency.

Laron Z, Iluz M, Kauli R.

Growth Horm IGF Res. 2012 Apr;22(2):49-52. doi: 10.1016/j.ghir.2012.02.005. Epub 2012 Mar 11. Review.

PMID:
22414926
9.

Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, Loeffler J, Biller BM, Klibanski A, Miller KK.

Clin Endocrinol (Oxf). 2012 Sep;77(3):430-8. doi: 10.1111/j.1365-2265.2012.04361.x.

10.

Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function.

Newman CB, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, Schwartzbard A, Kleinberg DL.

J Clin Endocrinol Metab. 2011 Jan;96(1):122-32. doi: 10.1210/jc.2010-1204. Epub 2010 Oct 6.

PMID:
20926529
11.

Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.

Valle D, Di Minno MN, Palmieri V, Pezzullo S, Cirillo F, Di Somma C, Di Minno G, Lombardi G.

J Endocrinol Invest. 2009 Dec;32(11):908-12. doi: 10.3275/6434. Epub 2009 Jul 17.

PMID:
19609105
12.

Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database.

Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, Fassbender W, Faust M, Kann PH, Wallaschofski H.

Growth Horm IGF Res. 2008 Dec;18(6):472-8. doi: 10.1016/j.ghir.2008.08.007. Epub 2008 Oct 1.

PMID:
18829359
13.

Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults.

Meyer S, Haist M, Schaefer S, Ivan D, Ittner JR, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Habbe N, Kann PH.

Pharmacogenomics. 2008 Aug;9(8):1017-26. doi: 10.2217/14622416.9.8.1017.

15.
16.

Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation.

Vlugt-Wensink KD, de Vrueh R, Gresnigt MG, Hoogerbrugge CM, van Buul-Offers SC, de Leede LG, Sterkman LG, Crommelin DJ, Hennink WE, Verrijk R.

Pharm Res. 2007 Dec;24(12):2239-48. Epub 2007 Oct 11.

17.

Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency.

Giavoli C, Bergamaschi S, Ferrante E, Ronchi CL, Lania AG, Rusconi R, Spada A, Beck-Peccoz P.

Clin Endocrinol (Oxf). 2008 Feb;68(2):247-51. Epub 2007 Sep 14.

PMID:
17868384
18.
19.

Effect of recombinant hGH (rhGH) replacement on gonadal function in male patients with organic adult-onset GH deficiency.

Giavoli C, Ferrante E, Ermetici F, Bergamaschi S, Ronchi CL, Lania AG, Ambrosi B, Spada A, Beck-Peccoz P.

Clin Endocrinol (Oxf). 2006 Dec;65(6):717-21.

PMID:
17121521
20.

A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile.

Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet SM.

Clin Endocrinol (Oxf). 2005 May;62(5):623-7.

PMID:
15853836

Supplemental Content

Loading ...
Support Center